已收盘 02-06 16:00:00 美东时间
+0.310
+8.05%
60 Degrees Pharma shares are trading lower. The company announced a partnership...
02-03 03:00
今日重点评级关注:瑞穗:维持Syndax制药"跑赢大市"评级,目标价从410美元升至600美元;HC Wainwright & Co.:维持60 Degrees Pharmaceuticals, Inc."买入"评级,目标价从6美元升至24美元
01-28 10:59
60 Degrees Pharmaceuticals shares are trading higher after the company announce...
01-22 21:07
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that infection
2025-12-29 21:11
6-month commercial pilot demonstrated increasing demand among prescribersExpansion plan includes doubling the number of sales reps, a new GoodRx partnership, and enhanced digital marketing campaignAdditional clinical
2025-12-11 21:19
今日重点评级关注:Benchmark:维持Grupo Televisa"买入"评级,目标价从9美元升至10美元;Truist Securities:维持迪尔股份"买入"评级,目标价从609美元升至612美元
2025-12-01 14:33
Ascendiant Capital analyst Lucas Ward maintains 60 Degrees (NASDAQ:SXTP) with a Buy and lowers the price target from $3 to $2.8.
2025-11-28 18:57
花旗上调Bilibili目标价升至27美元; 摩根士丹利上调英伟达目标价升至220美元;Ardent Health、Stubhub遭多家大行下调评级>>
2025-11-17 10:49
HC Wainwright & Co. analyst Matthew Keller assumes 60 Degrees (NASDAQ:SXTP) with a Buy rating and announces Price Target of $6.
2025-11-14 20:48
60 Degrees (NASDAQ:SXTP) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimate of $(1.21) by 45.45 percent. This is a 85.81 percent increase over losses of $(4.65) per share from the
2025-11-14 02:54